LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.
1/5 보강
[BACKGROUND] Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide.
APA
Lin JC, Huang TS, et al. (2026). LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.. Biology direct, 21(1). https://doi.org/10.1186/s13062-026-00735-1
MLA
Lin JC, et al.. "LDN-57444 sensitizes hepatocellular carcinoma cells to sorafenib by promoting ferroptosis through histone deacetylase 2 (HDAC2) inhibition.." Biology direct, vol. 21, no. 1, 2026.
PMID
41689036 ↗
Abstract 한글 요약
[BACKGROUND] Hepatocellular carcinoma (HCC) is still one of the leading causes of cancer-related mortality worldwide. Sorafenib is commonly used as first-line systemic treatment for advanced HCC, but the clinical benefits fall victim to either primary or acquired drug resistance. Modulating ferroptosis, a form of iron-dependent regulated cell death (RCD), has been increasingly explored in order to circumvent this chemoresistance.
[METHODS] We performed a pharmacogenomic screening analysis using the DepMap database to identify small molecules whose cytotoxicity patterns resemble those of known ferroptosis inducers. Among the candidates, LDN-57444 was selected for further evaluation. Its ability to enhance the anticancer activity of sorafenib was examined in PLC/PRF/5 and Hep3B HCC cell lines using cell viability assays, molecular docking, cellular thermal shift assays (CETSA), and siRNA-mediated gene silencing.
[RESULTS] In the HCC models tested, sorafenib alone did not induce ferroptosis, unlike some earlier reports. LDN-57444, previously described as an inhibitor of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), emerged as a strong ferroptosis sensitizer. Co-treatment with LDN-57444 and sorafenib led to pronounced synergistic cytotoxicity, and this effect was completely abolished by the ferroptosis inhibitor ferrostatin-1. Mechanistic analyses showed that the synergy is independent of UCH-L1. Structural modeling and target-engagement experiments indicated that histone deacetylase 2 (HDAC2) is the relevant molecular target. Silencing HDAC2, but not HDAC1, reduced sensitivity to the drug combination, supporting the idea that LDN-57444 enhances sorafenib activity by modulating HDAC2.
[CONCLUSION] Our findings demonstrate that LDN-57444 potentiates sorafenib-induced ferroptosis in HCC cells through an HDAC2-dependent mechanism. These results highlight the therapeutic potential of combining HDAC2 inhibitors with sorafenib to improve treatment responses in advanced HCC.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13062-026-00735-1.
[METHODS] We performed a pharmacogenomic screening analysis using the DepMap database to identify small molecules whose cytotoxicity patterns resemble those of known ferroptosis inducers. Among the candidates, LDN-57444 was selected for further evaluation. Its ability to enhance the anticancer activity of sorafenib was examined in PLC/PRF/5 and Hep3B HCC cell lines using cell viability assays, molecular docking, cellular thermal shift assays (CETSA), and siRNA-mediated gene silencing.
[RESULTS] In the HCC models tested, sorafenib alone did not induce ferroptosis, unlike some earlier reports. LDN-57444, previously described as an inhibitor of ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), emerged as a strong ferroptosis sensitizer. Co-treatment with LDN-57444 and sorafenib led to pronounced synergistic cytotoxicity, and this effect was completely abolished by the ferroptosis inhibitor ferrostatin-1. Mechanistic analyses showed that the synergy is independent of UCH-L1. Structural modeling and target-engagement experiments indicated that histone deacetylase 2 (HDAC2) is the relevant molecular target. Silencing HDAC2, but not HDAC1, reduced sensitivity to the drug combination, supporting the idea that LDN-57444 enhances sorafenib activity by modulating HDAC2.
[CONCLUSION] Our findings demonstrate that LDN-57444 potentiates sorafenib-induced ferroptosis in HCC cells through an HDAC2-dependent mechanism. These results highlight the therapeutic potential of combining HDAC2 inhibitors with sorafenib to improve treatment responses in advanced HCC.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s13062-026-00735-1.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.
- Enhanced efficacy and long-term survival with SBRT plus PD-1 inhibitors versus SBRT alone in unresectable HCC: a multicenter PSM study.
- Risks, Benefits, and Molecular Targets of Fenugreek Administration in the Treatment of Hepatocellular Carcinoma.
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.